Rapid Dose Announces Closing of Final Tranche of Common Share Private Placement
Rapid Dose Therapeutics Corp. (CSE: DOSE) has completed the second and final tranche of its equity private placement financing, raising $542,000 through the issuance of 3,188,233 common shares at $0.17 per share. Combined with the first tranche, the company has raised total gross proceeds of $851,000. The financing had a maximum capacity of $6,000,000. Proceeds will support research and development, capital expansion, debt repayment, and working capital needs. The issued shares are subject to a four-month hold period.
Rapid Dose Therapeutics Corp. (CSE: DOSE) ha completato la seconda e ultima tranche della sua raccolta fondi privata tramite azioni, raccogliendo 542.000 $ attraverso l'emissione di 3.188.233 azioni ordinarie a 0,17 $ per azione. Insieme alla prima tranche, l'azienda ha raccolto un totale di 851.000 $. La raccolta aveva una capacità massima di 6.000.000 $. I proventi supporteranno la ricerca e sviluppo, l'espansione dei capitali, il rimborso del debito e le esigenze di capitale circolante. Le azioni emesse sono soggette a un periodo di blocco di quattro mesi.
Rapid Dose Therapeutics Corp. (CSE: DOSE) ha completado la segunda y última fase de su financiación privada de capital, recaudando 542.000 $ mediante la emisión de 3.188.233 acciones comunes a 0,17 $ por acción. Combinado con la primera fase, la compañía ha recaudado un total de 851.000 $. La financiación tenía una capacidad máxima de 6.000.000 $. Los ingresos apoyarán la investigación y el desarrollo, la expansión del capital, el pago de deudas y las necesidades de capital de trabajo. Las acciones emitidas están sujetas a un período de restricción de cuatro meses.
Rapid Dose Therapeutics Corp. (CSE: DOSE)는 주식 사모 펀드 조달의 두 번째이자 마지막 분기를 완료했으며, 542,000 $을 3,188,233 주식의 일반 주식을 0.17 $로 발행함으로써 모금했습니다. 첫 번째 분기를 합쳐 회사는 총 851,000 $의 조달 자금을 마련했습니다. 이 자금 조달의 최대 한도는 6,000,000 $입니다. 수익은 연구 및 개발, 자본 확장, 부채 상환 및 운영 자본 필요를 지원하는 데 사용됩니다. 발행된 주식은 4개월의 보유 기간이 있습니다.
Rapid Dose Therapeutics Corp. (CSE: DOSE) a complété la deuxième et dernière tranche de son financement privé par actions, levant 542.000 $ grâce à l'émission de 3.188.233 actions ordinaires à 0,17 $ par action. En combinant avec la première tranche, la société a levé un total brut de 851.000 $. Le financement avait une capacité maximale de 6.000.000 $. Les fonds serviront à soutenir la recherche et le développement, l'expansion du capital, le remboursement de la dette et les besoins en fonds de roulement. Les actions émises sont soumises à une période de blocage de quatre mois.
Rapid Dose Therapeutics Corp. (CSE: DOSE) hat die zweite und letzte Tranche ihrer privaten Aktienplatzierungsfinanzierung abgeschlossen und 542.000 $ durch die Ausgabe von 3.188.233 Stammaktien zu einem Preis von 0,17 $ pro Aktie gesammelt. Zusammen mit der ersten Tranche hat das Unternehmen insgesamt 851.000 $ an Bruttoeinnahmen erzielt. Die Finanzierung hatte eine maximale Kapazität von 6.000.000 $. Die Einnahmen werden die Forschung und Entwicklung, die Kapazitätserweiterung, die Schuldenrückzahlung und die Bedürfnisse des Betriebskapitals unterstützen. Die ausgegebenen Aktien unterliegen einer Haltefrist von vier Monaten.
- Secured additional capital of $542,000 through private placement
- Total financing raised $851,000 for operations and debt reduction
- Funds allocated for R&D and capital expansion
- Only achieved 14.2% ($851,000) of maximum $6,000,000 financing target
- Share dilution through issuance of 3,188,233 new common shares
Burlington, Ontario--(Newsfile Corp. - October 30, 2024) - Rapid Dose Therapeutics Corp. (CSE: DOSE) ("RDT" or the "Company") is pleased to announce that it has closed a second and final tranche of its previously announced equity private placement financing (the "Financing") for aggregate gross proceeds of
The proceeds of the Financing will be used for research and development, capital expansion, repayment of debt and general working capital requirements.
The Financing allowed for a maximum of
About Rapid Dose Therapeutics Corp.
Rapid Dose Therapeutics is a Canadian biotechnology company revolutionizing drug delivery through innovation. The Company's flagship product QuickStrip™ is a thin, orally dissolvable film, that can be infused with an infinite list of active ingredients, including nutraceuticals, pharmaceuticals and vaccines, that are delivered quickly into the bloodstream, resulting in rapid onset of the active ingredient. For more information about the Company, visit www.rapid-dose.com.
Contacts:
RDT Investor Contact:
Mark Upsdell, CEO
mupsdell@rapid-dose.com
416-477-1052
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS:
Certain information in this news release may contain forward-looking information within the meaning of applicable securities laws. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as "may", "should", "anticipate", "expect", "potential", "believe", "intend", "will", "could", "are planned to", "are expected to" or the negative of these terms and similar expressions. Statements containing forward-looking information, including, without limitation, in this news release in particular, statements regarding the size and completion of the Financing and the use of proceeds from the Financing, and in general, in respect of the delivery of equipment and products using the QuickStrip™ product delivery method, the generation of recurring revenues, the plans, estimates, forecasts, projections, expectations or beliefs of RDT management as to future events or results, are believed to be reasonable based on information currently available to RDT management. Forward-looking statements necessarily involve known and unknown risks, including, without limitation, risks associated with general economic conditions; adverse industry events; marketing costs; loss of markets; termination of WLM agreements; future legislative and regulatory developments involving cannabis; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favourable terms; the cannabis industry in Canada generally, income tax and regulatory matters; the ability to implement its business strategies; competition; currency and interest rate fluctuations and other risks. Readers are cautioned that the foregoing list is not exhaustive. There can be no assurance that statements of forward-looking information, although considered reasonable by RDT management at the time of preparation, will prove to be accurate as there can be no assurance that the plans, intentions or expectations upon which they are based will occur. Actual results and future events could differ materially from those anticipated in such forward-looking statements. Readers should not place undue reliance on forward-looking statements. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release, and the Company expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful. This press release does not constitute an offer to sell or a solicitation of an offer to sell any of the securities described herein in the United States. The securities described in this news release have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act") or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/228401
FAQ
How much did Rapid Dose Therapeutics (RDTCF) raise in its final tranche of private placement?
What was the total amount raised by Rapid Dose Therapeutics (RDTCF) across both tranches?
What is the price per share for Rapid Dose Therapeutics (RDTCF) private placement?
How will Rapid Dose Therapeutics (RDTCF) use the proceeds from the private placement?
